Biomea Fusion, Inc. (BMEA) shareholders
BMEANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.56−0.05 (-7.89%)
Close on Nov 12, 2026Market cap $40.79MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
34.8%
25M of 72M shares
Institutional holders
61
10 new, 14 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $196.40K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| CVI Investments, Inc. Joint filing with Heights Capital Management, Inc. (9.90%) | 7,847,232 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (15.00%) | 5,355,867 | 15.00% | 13G (passive) amendment | Feb 9, 2024 |
| Blue Owl Capital Holdings LP | 4,451,219 | 5.92% | 13G (passive) | Dec 31, 2025 |
| Thomas Butler | 3,802,482 | 10.40% | 13G (passive) amendment | Dec 31, 2023 |
| Janus Henderson Group PLC | 3,750,000 | 5.00% | 13G (passive) | Nov 28, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BMEA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 8,814,946 | 12.16% | $12.96M | +1,587 | 0.00% |
| Vanguard Capital Management LLC | 2,829,927 | 3.90% | $4.16M | +232,627 | 0.00% |
| Marshall Wace, Llp | 2,049,802 | 2.83% | $3.01M | +851,251 | 0.00% |
| Aisling Capital Management LP | 2,048,757 | 2.83% | $3.01M | – | 0.64% |
| Renaissance Technologies LLC | 1,455,474 | 2.01% | $2.14M | +142,676 | 0.00% |
| Fideuram - Intesa Sanpaolo Private Banking S.P.A. | 723,176 | 1.00% | $1.06M | +166,140 | 0.03% |
| BlackRock, Inc. | 715,445 | 0.99% | $1.05M | +74,010 | 0.00% |
| Geode Capital Management, LLC | 708,854 | 0.98% | $1.04M | +160,668 | 0.00% |
| Susquehanna International Group, Llp | 612,735 | 0.85% | $900.72K | −17,130 | 0.00% |
| Mariner, LLC | 594,726 | 0.82% | $874.25K | −59,852 | 0.00% |
| Jane Street Group, LLC | 458,289 | 0.63% | $673.69K | +182,634 | 0.00% |
| UBS Group AG | 444,728 | 0.61% | $653.75K | −70,827 | 0.00% |
| XTX Topco Ltd | 406,879 | 0.56% | $598.11K | −123,663 | 0.01% |
| Two Sigma Investments, LP | 384,459 | 0.53% | $565.16K | −4,237 | 0.00% |
| Morgan Stanley | 367,021 | 0.51% | $539.52K | +20,279 | 0.00% |
| Vanguard Fiduciary Trust Co | 338,345 | 0.47% | $497.37K | +2,230 | 0.00% |
| MAI Capital Management | 289,100 | 0.40% | $424.98K | +200,000 | 0.00% |
| State Street Corp | 257,315 | 0.35% | $378.25K | +49,300 | 0.00% |
| Superstring Capital Management LP | 250,000 | 0.34% | $85.31K | – | 0.05% |
| Gsa Capital Partners Llp | 216,020 | 0.30% | $318.00K | +186,503 | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 61 | 25M | 34.8% | 10 / 22 | 11 / 14 | 3M | 2M |
| Q1 2026 | 65 | 24M | 33.6% | 17 / 16 | 13 / 9 | 6M | 2M |
| Q4 2025 | 60 | 23M | 32.0% | 8 / 16 | 18 / 19 | 5M | 7M |
| Q3 2025 | 73 | 25M | 34.6% | 11 / 22 | 24 / 25 | 3M | 7M |
| Q2 2025 | 87 | 29M | 39.7% | 29 / 22 | 24 / 37 | 12M | 5M |
| Q1 2025 | 95 | 21M | 29.6% | 10 / 32 | 29 / 21 | 2M | 3M |
| Q4 2024 | 108 | 23M | 31.7% | 32 / 28 | 29 / 12 | 3M | 3M |
| Q3 2024 | 88 | 23M | 32.4% | 13 / 28 | 27 / 31 | 4M | 2M |
| Q2 2024 | 107 | 24M | 32.5% | 30 / 33 | 28 / 25 | 4M | 13M |
| Q1 2024 | 104 | 32M | 44.3% | 19 / 32 | 29 / 15 | 6M | 2M |
| Q4 2023 | 100 | 28M | 39.2% | 30 / 26 | 26 / 15 | 3M | 5M |
| Q3 2023 | 85 | 30M | 41.6% | 12 / 35 | 20 / 17 | 3M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
23 funds held BMEA in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BMEA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 2,711,793 | 3.74% | $3.74M | 0.00% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,122,086 | 2.93% | $3.12M | 0.00% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 907,147 | 1.25% | $1.25M | 0.00% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 804,702 | 1.11% | $1.11M | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 634,141 | 0.87% | $932.19K | 0.00% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 452,663 | 0.62% | $624.67K | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 291,584 | 0.40% | $402.39K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 231,015 | 0.32% | $339.59K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 109,135 | 0.15% | $150.61K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 84,600 | 0.12% | $124.36K | 0.08% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 82,413 | 0.11% | $113.73K | 0.00% | May 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 59,251 | 0.08% | $87.10K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 51,944 | 0.07% | $71.68K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 37,201 | 0.05% | $54.69K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 36,499 | 0.05% | $53.65K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael J.M. Hitchcock | Interim CEO, Director | 115,000 | 0.16% | Apr 3, 2026 |
| Rainer M. Erdtmann | See Remarks, Director | 987,041 | 1.36% | Apr 3, 2026 |
| Franco Valle | Chief Financial Officer | 42,995 | 0.06% | Dec 2, 2024 |
| Julianne Averill | Director | – | – | Jun 12, 2026 |
| Eric Aguiar | Director | – | – | Jun 12, 2026 |
| Elizabeth Faust | Director | – | – | Jun 12, 2026 |
| Sumita Ray | Director | – | – | Jun 12, 2026 |
| Cormorant Global Healthcare Master Fund, LP | – | 3,570,872 | 4.93% | Aug 1, 2025 |
| Cormorant Asset Management, LP | – | 3,170,872 | 4.37% | Aug 1, 2025 |
| Bihua Chen | – | 3,570,872 | 4.93% | Aug 1, 2025 |
| Private Healthcare Fund III LP Cormorant | – | – | – | Aug 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rainer M. Erdtmann See Remarks, Director | Dec 31, 2025 | Gift | −50,600 | – | – | 672,427 |
| Rainer M. Erdtmann See Remarks, Director | Dec 31, 2025 | Gift | +50,000 | – | – | 70,000 |
| Rainer M. Erdtmann See Remarks, Director | Dec 31, 2025 | Gift | −50,000 | – | – | 572,427 |
| Rainer M. Erdtmann See Remarks, Director | Dec 31, 2025 | Gift | +50,000 | – | – | 70,000 |
| Rainer M. Erdtmann See Remarks, Director | Dec 31, 2025 | Gift | −50,000 | – | – | 622,427 |
| Rainer M. Erdtmann See Remarks, Director | Dec 31, 2025 | Gift | +50,600 | – | – | 70,000 |
| Rainer M. Erdtmann See Remarks, Director | Dec 11, 2025 | Buy | +30,000 | $1.43 | $42.90K | 723,027 |
| Michael J.M. Hitchcock Interim CEO, Director | Dec 2, 2025 | Buy | +100,000 | $0.99 | $99.00K | 115,000 |
| Rainer M. Erdtmann See Remarks, Director | Dec 1, 2025 | Buy | +10,000 | $1.05 | $10.50K | 693,027 |
| Rainer M. Erdtmann See Remarks, Director | Nov 28, 2025 | Buy | +40,000 | $1.10 | $44.00K | 683,027 |
| Rainer M. Erdtmann See Remarks, Director | Jan 31, 2025 | Gift | −10,000 | – | – | 643,027 |
| Rainer M. Erdtmann See Remarks, Director | Jan 31, 2025 | Gift | −10,000 | – | – | 653,027 |
| Rainer M. Erdtmann See Remarks, Director | Jan 31, 2025 | Gift | +10,000 | – | – | 19,400 |
| Rainer M. Erdtmann See Remarks, Director | Jan 31, 2025 | Gift | −10,000 | – | – | 663,027 |
| Rainer M. Erdtmann See Remarks, Director | Jan 31, 2025 | Gift | +10,000 | – | – | 20,000 |
| Rainer M. Erdtmann See Remarks, Director | Jan 31, 2025 | Gift | +10,000 | – | – | 20,000 |
| Rainer M. Erdtmann See Remarks, Director | Jan 28, 2025 | Gift | −40,000 | – | – | 673,027 |
| Franco Valle Chief Financial Officer | Nov 30, 2024 | Award | +495 | $6.15 | $3.04K | 42,995 |
| Michael J.M. Hitchcock Director | Sep 30, 2024 | Buy | +10,000 | $10.06 | $100.60K | 15,000 |
| Franco Valle Chief Financial Officer | Jun 11, 2024 | Buy | +12,509 | $4.43 | $55.41K | 42,500 |
| Franco Valle Chief Financial Officer | May 31, 2024 | Award | +4,448 | $3.78 | $16.81K | 29,991 |
| Juan Pablo Frias Chief Medical Officer | May 31, 2024 | Award | +349 | $8.94 | $3.12K | 349 |
| Rainer M. Erdtmann President and COO, Director | Dec 29, 2023 | Gift | +3,000 | – | – | 10,000 |
| Rainer M. Erdtmann President and COO, Director | Dec 29, 2023 | Gift | −3,000 | – | – | 728,027 |
| Rainer M. Erdtmann President and COO, Director | Dec 29, 2023 | Gift | +3,000 | – | – | 9,400 |
| Rainer M. Erdtmann President and COO, Director | Dec 29, 2023 | Gift | +3,000 | – | – | 10,000 |
| Rainer M. Erdtmann President and COO, Director | Dec 29, 2023 | Gift | −12,000 | – | – | 713,027 |
| Rainer M. Erdtmann President and COO, Director | Dec 29, 2023 | Gift | −3,000 | – | – | 731,027 |
| Rainer M. Erdtmann President and COO, Director | Dec 29, 2023 | Gift | −3,000 | – | – | 725,027 |
| Franco Valle Chief Financial Officer | Nov 30, 2023 | Award | +1,345 | $3.78 | $5.08K | 25,543 |
| A2A Pharmaceuticals, Inc. 10% owner | Jun 1, 2023 | Sale | −50,000 | $34.56 | $1.73M | 3,500,000 |
| A2A Pharmaceuticals, Inc. 10% owner | May 31, 2023 | Sale | −75,000 | $33.81 | $2.54M | 3,550,000 |
| Franco Valle Chief Financial Officer | May 31, 2023 | Award | +4,273 | $3.78 | $16.15K | 24,198 |
| A2A Pharmaceuticals, Inc. 10% owner | May 12, 2023 | Sale | −25,000 | $33.84 | $846.00K | 3,625,000 |
| A2A Pharmaceuticals, Inc. 10% owner | May 9, 2023 | Sale | −150,000 | $34.50 | $5.18M | 3,650,000 |
| A2A Pharmaceuticals, Inc. 10% owner | May 8, 2023 | Sale | −100,000 | $33.99 | $3.40M | 3,800,000 |
| A2A Pharmaceuticals, Inc. 10% owner | Apr 20, 2023 | Sale | −200,000 | $29.12 | $5.82M | 3,900,000 |
| A2A Pharmaceuticals, Inc. 10% owner | Mar 31, 2023 | Sale | +200,000 | $31.25 | $6.25M | 4,100,000 |
| A2A Pharmaceuticals, Inc. 10% owner | Mar 31, 2023 | Sale | −200,000 | $31.25 | $6.25M | 4,100,000 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Mar 30, 2023 | Buy | +400,000 | $30.00 | $12.00M | 3,570,872 |
| Rainer M. Erdtmann President & COO, Director | Dec 28, 2022 | Gift | −4,000 | – | – | 808,027 |
| Rainer M. Erdtmann President & COO, Director | Dec 28, 2022 | Gift | +4,000 | – | – | 6,400 |
| Rainer M. Erdtmann President & COO, Director | Dec 28, 2022 | Gift | −4,000 | – | – | 812,027 |
| Rainer M. Erdtmann President & COO, Director | Dec 28, 2022 | Gift | +4,000 | – | – | 7,000 |
| Rainer M. Erdtmann President & COO, Director | Dec 28, 2022 | Gift | −4,000 | – | – | 804,027 |
| Rainer M. Erdtmann President & COO, Director | Dec 28, 2022 | Gift | +4,000 | – | – | 7,000 |
| Rainer M. Erdtmann President & COO, Director | Dec 28, 2022 | Gift | −70,000 | – | – | 734,027 |
| Franco Valle Chief Financial Officer | Nov 30, 2022 | Award | +2,518 | $3.78 | $9.52K | 19,925 |
| Michael J.M. Hitchcock Director | Nov 14, 2022 | Buy | +5,000 | $7.93 | $39.65K | 5,000 |
| Franco Valle Chief Financial Officer | Nov 11, 2022 | Buy | +4,100 | $7.63 | $31.28K | 17,407 |
| Rainer M. Erdtmann President & COO, Director | Aug 19, 2022 | Gift | −16,000 | – | – | 816,027 |
| Rainer M. Erdtmann President & COO, Director | Aug 16, 2022 | Gift | −17,100 | – | – | 832,027 |
| A2A Pharmaceuticals, Inc. 10% owner | Aug 16, 2022 | Buy | −30,684 | $13.87 | $425.59K | 4,300,000 |
| A2A Pharmaceuticals, Inc. 10% owner | Jul 21, 2022 | Sale | −34,658 | $11.21 | $388.52K | 4,330,684 |
| Rainer M. Erdtmann President & COO, Director | Jul 1, 2022 | Gift | −100,000 | – | – | 849,127 |
| A2A Pharmaceuticals, Inc. 10% owner | Jun 24, 2022 | Sale | −34,658 | $11.76 | $407.58K | 4,365,342 |
| Biomea Health, LLC 10% owner | Jun 1, 2022 | Other | −4,365,342 | – | – | 0 |
| Franco Valle Chief Financial Officer | May 31, 2022 | Award | +3,307 | $4.67 | $15.44K | 13,307 |
| Franco Valle Chief Financial Officer | Jan 14, 2022 | Buy | +10,000 | $8.68 | $86.80K | 10,000 |
| Sotirios Stergiopoulos Director | Sep 17, 2021 | Buy | +34,658 | $10.96 | $379.85K | 4,400,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
22.21%
15M shares short
Days to cover
8.4
At 2M shares a day
Change since last report
-3.2%
From 16M shares
Short volume, 20 days
50.8%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Biomea Fusion's stock actually held short. Settlement fails (shares not delivered on time) peaked at 459,121 shares on Sep 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| A2A Pharmaceuticals, Inc. 10% Stockholder | May 19, 2023 | 1,500,000 | $48.20M | May 19, 2023 | Founder's Shares |
| A2A Pharmaceuticals, Inc. Stakeholder | Apr 27, 2023 | 400,000 | $12.00M | Apr 27, 2023 | Pre-IPO Owner |
| A2A Pharmaceuticals, Inc. 10% Stockholder | Apr 20, 2023 | 200,000 | $5.55M | Apr 20, 2023 | Founder's Shares |
See a number that looks wrong?